ID | 115670 |
Author |
Qi, Guangying
Guilin Medical University|Prefectural University of Hiroshima
Kudo, Yasusei
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Tang, Bo
Guilin Medical University
Liu, Tian
Guilin Medical University
Jin, Shengjian
Guilin Medical University
Liu, Jing
Guilin Medical University
Zuo, Xiaoxu
Guilin Medical University
Mi, Sisi
Guilin Medical University
Shao, Wenhuan
Guilin Medical University
Ma, Xiaojuan
Guilin Medical University
Tsunematsu, Takaaki
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Ishimaru, Naozumi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Zeng, Sien
Guilin Medical University
Tatsuka, Masaaki
Prefectural University of Hiroshima
Shimamoto, Fumio
Prefectural University of Hiroshima
|
Keywords | PARP6
Survivin
colorectal cancer
tumor suppressor
prognosis
|
Content Type |
Journal Article
|
Description | Poly (ADP-ribose) polymerases (PARPs) are enzymes that transfer ADP-ribose groups to target proteins and are involved in a variety of biological processes. PARP6 is a novel member, and our previous findings suggest that PARP6 may act as a tumor suppressor via suppressing cell cycle progression. However, it is still unclear that PARP6 function besides growth suppression in colorectal cancer (CRC). In this study, we examined tumor suppressive roles of PAPR6 in CRC cells both in vitro and in vivo. We found that PARP6 inhibited colony formation, invasion and migration as well as cell proliferation. Moreover, ectopic overexpression of PARP6 decreased Survivin expression, which acts as an oncogene and is involved in apoptosis and mitosis. We confirmed the inverse correlation between PARP6 and Survivin expression in CRC cases by immunohistochemistry. Importantly, CRC cases with downregulation of PARP6 and upregulation of Survivin showed poor prognosis. In summary, PARP6 acts as a tumor suppressor via downregulating Survivin expression in CRC. PARP6 can be a novel diagnostic and therapeutic target together with Survivin for CRC.
|
Journal Title |
Oncotarget
|
ISSN | 19492553
|
Publisher | Impact Journals
|
Volume | 7
|
Issue | 14
|
Start Page | 18812
|
End Page | 18824
|
Published Date | 2016-02-25
|
Rights | This is licensed under a Creative Commons Attribution 3.0 License(https://creativecommons.org/licenses/by/3.0/).
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Oral Sciences
|